Publications by authors named "J Karolova"
Our knowledge of genetic aberrations, that is, variants and copy number variations (CNVs), associated with mantle cell lymphoma (MCL) relapse remains limited. A cohort of 25 patients with MCL at diagnosis and the first relapse after the failure of standard immunochemotherapy was analyzed using whole-exome sequencing. The most frequent variants at diagnosis and at relapse comprised six genes: TP53, ATM, KMT2D, CCND1, SP140, and LRP1B.
View Article and Find Full Text PDFMultiple myeloma (MM) is an incurable, malignant B cell disorder characterized by frequent relapses and a poor prognosis. Thus, new therapeutic approaches are warranted. The phosphatidylinositol-3-kinase (PI3K) pathway plays a key role in many critical cellular processes, including cell proliferation and survival.
View Article and Find Full Text PDFArticle Synopsis
- * A study analyzed 15 different PDX models from various NHL types, confirming that PDXs retained the genetic diversity of the original tumors through whole exome sequencing (WES).
- * However, the tumor microenvironment (TME) in PDXs showed notable differences, including altered cell morphology, reduced immune cell presence, and lower blood vessel density, suggesting that while genetic profiles are maintained, the PDXs do not fully replicate the original cancer environment.
Article Synopsis
- MCL1 protein is commonly overexpressed in various cancers, including B-cell non-Hodgkin lymphomas (B-NHL), and its specific inhibitor, S63845, was studied for its effectiveness in treating these cancers.
- The research found that the expression levels of BCL2 protein significantly affect how lymphoma cells respond to S63845, with BCL2-positive cells showing resistance and BCL2-negative cells being more susceptible to treatment.
- Combining S63845 with another drug, venetoclax, proved to be particularly effective for overcoming resistance in BCL2-positive lymphoma models, highlighting the importance of both MCL1 and BCL2 levels in treatment outcomes.
Non-Hodgkin lymphomas (NHLs) are lymphoid malignancies of B- or T-cell origin. Despite great advances in treatment options and significant improvement of survival parameters, a large part of NHL patients either present with a chemotherapy-refractory disease or experience lymphoma relapse. Chemotherapy-based salvage therapy of relapsed/refractory NHL is, however, capable of re-inducing long-term remissions only in a minority of patients.
View Article and Find Full Text PDF